NEULAND LABORATORIES
Back to Balance Sheet
|
NEULAND LABORATORIES Last 5 Year Contingent Liabilities History
[Consolidated]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 | |
|---|---|---|---|---|---|
| Contingent Liabilities | ₹8.97 Cr | ₹28 Cr | ₹91 Cr | ₹75 Cr | ₹105 Cr |
What is the latest Contingent Liabilities ratio of NEULAND LABORATORIES ?
| Year | Contingent Liabilities |
|---|---|
| Mar2025 | ₹8.97 Cr |
| Mar2024 | ₹28 Cr |
| Mar2023 | ₹91 Cr |
| Mar2022 | ₹75 Cr |
| Mar2021 | ₹105 Cr |
How is Contingent Liabilities of NEULAND LABORATORIES Trending?
| Years | Contingent Liabilities | % Change | |
|---|---|---|---|
| Mar2025 | ₹8.97 Cr | -67.65 | |
| Mar2024 | ₹28 Cr | -69.60 | |
| Mar2023 | ₹91 Cr | 22.14 | |
| Mar2022 | ₹75 Cr | -28.68 | |
| Mar2021 | ₹105 Cr | - | |
Compare Contingent Liabilities of peers of NEULAND LABORATORIES
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| NEULAND LABORATORIES | ₹19,134.7 Cr | 13% | 18.5% | 22.4% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹397,018.0 Cr | -2.3% | -8.5% | -3% | Stock Analytics | |
| DIVIS LABORATORIES | ₹162,454.0 Cr | 5.3% | -3.4% | 3.4% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹140,702.0 Cr | 3.7% | -4.9% | 26% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹102,830.0 Cr | 1.2% | -4.2% | 5.3% | Stock Analytics | |
| CIPLA | ₹99,325.0 Cr | 2.4% | -7.2% | -18.1% | Stock Analytics | |
NEULAND LABORATORIES Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| NEULAND LABORATORIES | 13% |
18.5% |
22.4% |
| SENSEX | 5.8% |
-1.7% |
1.2% |
You may also like the below Video Courses